Zai Lab Announces $250 Million Private Placement
Zai Lab announced a $250 million PIPE financing: the sale of 11,340,000 ADSs at $22.04 per ADS to a syndicate of new and existing institutional investors. The raise is led by TCGX and includes blue-chip healthcare investors such as RA Capital, RTW, Wellington Management, and Balyasny, with Leerink Partners as exclusive placement agent. Proceeds will primarily fund global development of zocilurtatug pelitecan (zoci), the company's DLL3-targeting antibody-drug conjugate. The deal is expected to close on or about October 27, 2026, and the company will file a resale registration statement for the new ADSs.
Key figures
- Deal Value Usd
- 250000000
- Offering Price
- 22.04
- Shares Offered
- 11340000
- Ads ratio
- 1 ADS = 10 ordinary shares
- Instrument
- PIPE (private placement of ADSs)
- Expected close
- on or about October 27, 2026
- Use of proceeds
- global development of zocilurtatug pelitecan (DLL3-targeting ADC)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.